←
Drug Channels9,229 posts
Drug Channels avatar

Drug Channels

@DrugChannels

Expert insights on pharmaceutical economics and the drug distribution system.

◷ Joined March 2009▧ 2,874 Photos and videos
Drug Channels avatar
Drug Channels@DrugChannels·7h

What happens to pharmacy benefit design and community pharmacies as PBM markets become more concentrated? --- Researchers from the National Pharmaceutical Council examined PBM market concentration and formulary structures across states from 2016 to 2025. Their sample included 267 million enrollees in 2025. They found: 📈 Average state-level PBM market concentration, measured by the Herfindahl-Hirschman Index (HHI), increased from 1,235 to 3,002. ↳ For context, under current DOJ/FTC guidelines, an HHI above 1,800 signals high concentration and a risk of market power. 💊 The share of enrollees in formularies with more than three tiers increased from 29.8% to 40.3%. ↳ Formularies with more than 3 tiers may include a specialty tier, which typically imposes higher cost sharing on patients. 📊 Across the state-years studied, 46.3% of the population in highly concentrated PBM markets lived in counties with net community pharmacy closures, compared with 18.2% in unconcentrated markets. --- The study shows an association. It does not establish that PBM concentration caused the increase in tiers or pharmacy closures. Many factors could contribute, including changes in the mix of drugs available, growth in specialty therapies, plan sponsor benefit design choices, and the use of tiers to encourage preferred products and negotiate manufacturer concessions. The number of tiers also doesn’t tell us everything about what patients pay. A fourth tier may carry higher cost sharing, but copayments, coinsurance, deductibles, and the drugs a patient needs all matter too. In our recent Drug Channels analysis of employer benefits, we found that HSA-qualified plans often had fewer tiers than other plans--but workers in those tiered benefits were more likely to face coinsurance for higher-tier drugs. Pharmacy closures have been very common the last few years, but the impact of a pharmacy closure depends on where it happens. In another Drug Channels blog, we described the pharmacy shakeout as K-shaped: patients in a dense market may have several nearby alternatives, while a rural community can lose its only pharmacy. --- Ultimately the NPC study is using data to show trends that can impact patient access to drugs. These results are more evidence on the potential links between PBM concentration and patient access. Policymakers may be interested 👀

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·11h

We’re delighted to welcome @GoodRx as a Platinum Sponsor of #DCLF2027! Don’t miss the opportunity to connect with @GoodRx and top industry leaders as we explore the challenges and opportunities shaping the future of drug channels. ✨ Learn more about available sponsorship opportunities: hmpglobalevents.com/drugchan… 📅 March 15-17, 2027 📍 JW Marriott Miami Turnberry Resort and Spa 🎟️ Request an invite: hmp-global.swoogo.com/dclf27…

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 17

We’re excited to share that #DCLF2027 returns to Miami, Florida, March 15-17, 2027, with leading drug pricing expert @A_Ciaccia joining as moderator. Now in its third year, this invitation-only forum will feature: • Discussion on the issues defining the future of the drug channel • Perspectives from leading industry experts • Focused sessions on critical developments, including “340B at an Inflection Point” and “All Roads Lead to GLP-1s” Interested in joining us? Request your invitation today: lnkd.in/efYWhzcu

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 17

Looking for something to talk about at Thanksgiving? How about PBM acquisitions, Medicare drug negotiation, and 340B hospital spending? --- In this month’s Drug Channels news roundup, we cover: 🔹 The PBM Shakeout Reaches VytlOne 🔹 Medicare Negotiation Meets New Formulations 🔹 Two Very Different Part D Premium Projections 🔹 A Closer Look at 340B Hospital Drug Spending I also included my Medicare Part D terms cheatsheet for anyone who needs a reference during annual enrollment. Read the full news roundup here 🦃 drugch.nl/4kgGBdY 🍗 Your family may prefer talking about football. Their loss.

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 16

“Your drug is covered” can still leave a patient asking, “How am I going to pay for it?” --- Insurance coverage and affordable access can be very different experiences. ↳ A clinically appropriate prescription can still be initially rejected. ↳ A covered drug can still cost less outside insurance. ↳ And patients can be grateful for treatment while frustrated by its cost. All of these experiences belong in the conversation about whether pharmacy benefits are doing what they're supposed to do.

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 16

From PHIL: 𝗧𝗵𝗲 𝗗𝗶𝗿𝗲𝗰𝘁-𝘁𝗼-𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆: 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗣𝗵𝗮𝗿𝗺𝗮’𝘀 𝗗𝗧𝗣 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗳𝗼𝗿 𝗟𝗮𝘀𝘁𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁 Download the report: The DTP Breakthrough: A Deep Dive on Pharma’s Direct-to-Patient Next Generation 👉🏻 drugch.nl/4iqW8qs Read the article: drugch.nl/4kGosq8 #sponsored

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 15

Many 340B debates treat hospitals and federal grantees as if they operate the same way. They don't. Here's how they're different. --- Most 340B discussions on LinkedIn miss how differently hospitals and federal grantees work within the same statute. Here are some major contrasts: 1️⃣ Qualification Paths ↳ Hospitals qualify for 340B if they are nonprofit or government-affiliated, fall into an eligible CMS hospital type, and meet minimum low-income care thresholds ↳ However, according to the GAO, HRSA’s oversight of 340B hospital eligibility is weak, relying heavily on unreliable self-reported data and limited audits ↳ Federal grantees qualify through categorical inclusion tied to federal program funding and program rules Here's the full list of entities that are eligible to participate in 340B: 🏥 Disproportionate share hospitals (the vast majority of all 340B purchases) 🏥 Critical access hospitals 🏥 Children's hospitals 🏥 Freestanding cancer hospitals 🏥 Rural referral centers 🏥 Sole community hospitals - 🏛️ Federally qualified health centers 🏛️ Black Lung clinics 🏛️ Family planning clinics 🏛️ Hemophilia treatment centers 🏛️ Native Hawaiian health centers 🏛️ Ryan White AIDS Drug Assistance Program 🏛️ Ryan White grantees (other) 🏛️ Sexually transmitted diseases grantees 🏛️ Tuberculosis grantees 🏛️ Urban Indian organizations 2️⃣ Mission Requirements ↳ Hospitals: No statutory charity care or patient discount requirements ↳ Grantees: Explicit affordability mandates (sliding fee scales, payer of last resort status) 3️⃣ Revenue Generation ↳ Hospitals monetize 340B through reimbursement spreads on high-cost outpatient drugs like oncology or autoimmune drugs ↳ Grantees typically fill lower-cost drugs like anti-infectives for HIV and hepatitis C ↳ For Minnesota in 2024, this resulted in 98% of the net profit going to hospitals and 2% to federal grantees 4️⃣ Contract Pharmacy Dynamics ↳ Both use contract pharmacies and massively scaled number of contract pharmacies post-2010 ↳ Hospitals have dramatically more revenue flowing through their contract pharmacy relationships ↳ Many federal grantees lack in-house pharmacies, so contract pharmacies allow for 340B revenue on prescription drugs filled outside those Covered Entities --- The CBO specifically notes hospitals receive larger reimbursements and generate net revenues from 340B, especially on provider-administered drugs and outpatient infusion. Hospitals accounted for 87% of the $100B in 340B drug purchases in 2025. Federal grantees operate under tighter program constraints with less exposure to high-margin specialty drugs. Understanding these differences is essential for having 340B discussions about reform. Is the growing issue with 340B expansion at hospitals (not federal grantees) a little clearer now? 🔗 Sources: HRSA eligibility hrsa.gov/opa/eligibility-and… CBO report cbo.gov/system/files/2025-09… Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care drugch.nl/4e533DS The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform? drugch.nl/45zs9oM

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 13

Feds have arrested a top official at an Alternative Funding Program company. Do you now see the risks you're taking with AFPs? --- Alternative Funding Programs (AFPs), also called specialty carve-outs, represent an approach for plan sponsors to access manufacturer patient support funding alongside traditional formulary management and copay assistance programs. Adoption remains limited for employers and is even lower for health plans due to legal(!!) and regulatory concerns. Here's how AFPs operate: 1️⃣ Specialty drugs excluded from plan formulary ↳ Patients have no coverage through their primary benefit 2️⃣ Third-party vendors administer excluded drugs ↳ Companies like CANARX (where top officials were arrested Sunday) coordinate care ↳ Help patients apply for manufacturer Patient Assistance Programs (PAPs) ↳ No cost to the patient 3️⃣ Prescriptions filled through manufacturer-funded specialty hubs ↳ Some vendors source from pharmacies outside the US when PAPs restrict use ↳ Manufacturer pays full prescription and pharmacy service costs 4️⃣ Plan pays vendor fees up to 30% of drug's list price ↳ Framed as "cost avoidance" fee for plan savings --- The risks are substantial and growing: Ethical violations: Commercial payers access charitable funds meant for underinsured patients ↳ Financially sound payers compete with truly needy patients for limited resources Patient access barriers--patients using AFP are: ↳ 47x more likely to experience treatment gaps ↳ Waiting 4x longer to start treatment ↳ 9x more likely to have adverse clinical outcomes Legal and safety violations: ↳ International sourcing violates FDA import laws and Drug Supply Chain Security Act ↳ ERISA compliance issues and fiduciary duty violations for self-insured plans ↳ Products may not have undergone FDA approval processes if sourced from foreign countries Clinical integrity issues: ↳ Non-medical switching: Plans direct patients to products with favorable PAP programs rather than most clinically appropriate options ↳ Treatment delays and gaps compromise patient outcomes Hidden financial costs: ↳ Higher administrative costs due to carve-out coordination ↳ Vendor fees reaching 25%+ of total PAP funds ↳ Reduced rebates and discounts from primary benefit design --- About 75% of employers and health plans view AFPs as unsustainable long-term. Looks like we have some more proof they may be right. Sources: 🔗 Arrest story cnbc.com/2026/11/11/canarx-o… 📖 AFP facts: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers drugch.nl/pharmacy

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 12

Medicare beneficiaries in traditional Medicare were 50% more likely to use a drug discount website than those in Medicare Advantage. --- In a @commonwealthfnd survey conducted in 2025, beneficiaries reported using a discount website (e.g., GoodRx, Cost Plus Drugs, BlinkRx, Amazon Pharmacy, TrumpRx) in the prior 12 months: 💊 Traditional Medicare: 21% 💊 Medicare Advantage: 14% Among everyone who used a discount site, 57% said the price was lower than their cost sharing under insurance. ↳ Another 28% used one to access a drug their plan didn’t cover. The survey compared traditional Medicare with Medicare Advantage, but it didn't answer why there's a difference. --- The way Medicare Advantage plans finance benefits is part of the context. MA plans can use Medicare rebate dollars to reduce Part D premiums and provide enhanced drug benefits. Standalone PDPs don’t have access to those same rebate dollars. Conventional MA plans allocated an average of $51 PMPM toward Part D premium reductions in 2026 (MedPAC). That can make MAPDs look more attractive, but these plans are still facing tradeoffs elsewhere in the MA benefit package. ↳ The additional value being added to MAPDs (e.g., supplemental benefits) has been decreasing since the IRA benefit redesign started. It's just not showing up in the Part D side as much because MAPDs have more flexibility in how they shift the new costs. --- Discount websites can offer lower prices and access to drugs a plan doesn’t cover. However, any spending outside Part D generally won’t count toward the annual out-of-pocket limit. A lower price today could mean higher costs later in the year if the patient was going to hit the OOP limit anyways. If you can find a better deal than your Part D plan, should that count towards your OOP limit? Sources: 🔗 The Commonwealth Fund, Why Are Medicare Beneficiaries Using Prescription Drug Discount Websites? commonwealthfund.org/blog/20… 🔗 MedPAC, The Medicare Advantage program: Status report, Chapter 12 medpac.gov/wp-content/upload… 🔗 Milliman, MA value added is down since 2024 linkedin.com/feed/update/urn…

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 12

🎉 Our sponsor lineup for #DCLF2027 is growing! We’re excited to recognize some of the organizations already committed to supporting the Drug Channels Leadership Forum 2027, with more sponsors to be announced! These organizations are helping bring together top industry leaders to explore the challenges, opportunities, and trends shaping the future of drug channels. Join us in welcoming our sponsors! 💎 DIAMOND SPONSORS AssistRx Gifthealth 🏆 PLATINUM SPONSORS BlinkRx GoodRx 🥈 SILVER SPONSORS Archbow Consulting Caretria Courier Health Lumicera Health Services PHIL PROspectus PhRMA RedSail Technologies RIS Rx Sempre Health 👏 Thank you to all our sponsors for supporting #DCLF2027! We look forward to connecting with you in Miami. ✨ Interested in becoming a sponsor? Explore available opportunities: hmpglobalevents.com/drugchan… 📅 March 15–17, 2027 📍 JW Marriott Miami Turnberry Resort & Spa 🎟️ Request an invitation: hmp-global.swoogo.com/dclf27… #DrugChannels #PharmacyLeadership #DCLF2027

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 11

A manufacturer’s list price and refund method could determine whether a pharmacy stocks an MFP drug. --- Under the Part D Maximum Fair Price (MFP) process, the manufacturer’s refund method can change the economics of a MFP drug at the pharmacy. The pharmacy may acquire a drug near its wholesale acquisition price (WAC), then be reimbursed at the lower MFP plus a dispensing fee. The pharmacy would have to carry the debt until the manufacturer’s refund arrives. In a Milliman example from a recent white paper, a pharmacy buys a MFP drug for $10,000 and receives $6,000 at the point of sale. That leaves about $4,000 tied up (per MFP drug dispensed) while the pharmacy waits for the refund. --- The refund benchmark matters, too. With the Standard Default Refund Amount, the manufacturer refunds the difference between WAC and MFP. For a community pharmacy whose prior reimbursement was below WAC, this can let the pharmacy retain its acquisition discount. We break down that math in this blog 👉🏻 drugch.nl/45zrjZa A contract price refund is based on what the pharmacy actually paid. Where the pharmacy’s prior margin depended on that acquisition discount, this approach can compress the margin until it's essentially just the dispensing fee. --- Timing of payment can also become an issue--NCPA found 67% of pharmacies waited more than 22 days for manufacturer refunds, and about 22% waited more than 28 days. So the stocking decision is about more than the final margin. It also depends on how much cash the pharmacy must carry and how long it waits to get paid. You can see how a pharmacy with moderate MFP volume could have cash flow issues if (using the Milliman hypothetical example from the paper) each claim requires an extra $4,000 of cash flow/credit line. Lowering the WAC helps address this issue for pharmacies, which is another of the pressures pushing towards a Net Pricing Drug Channel #NPDC

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 11

Federal policy is moving quickly. How will the drug channel respond? From IRA implementation and Medicare pricing changes to Part D reform and most-favored-nation (MFN) concepts, federal actions are influencing manufacturer strategy, channel economics, and patient access. On Tuesday, March 16, “From Policy to Practice: How Federal Reform Is Reshaping the Drug Channel” at the 2027 Drug Channels Leadership Forum will explore what these changes mean in practice and where their biggest effects could emerge. Meet The Panelists ▪️ Joel White, Head of Health Practice | Monument Advocacy ▪️ Conor Sheehey, MA, Director | Leavitt Partners ▪️ Rena Conti, Professor | Boston University Questrom School of Business, Department of Markets, Public Policy and Law Moderated by Jennifer Snow, MPH, Founder | Apteka 📅 March 15–17, 2027 📍 JW Marriott Miami Turnberry Resort & Spa Request your invitation to take part in the conversation: hmp-global.swoogo.com/dclf27 Invitation only. No press. No recordings. #DCLF2027 #DrugChannels #HealthPolicy #DrugPricing

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 10

Lower drug spending for an employer doesn’t necessarily mean lower costs for its employees. An employer can save while patients pay more. --- In the latest Drug Channels article, we examine how pharmacy benefit design divides costs and savings between employers and patients, using data from KFF’s 2026 Employer Health Benefits Survey. A few findings to spike your interest: 🔹 71% of workers in non-HSA-qualified plans have four or more drug benefit tiers, compared with 41% in HSA-qualified plans. 🔹 Among workers in plans with at least three tiers, 52% in HSA-qualified plans face coinsurance for preferred drugs, compared with 15% in non-HSA-qualified plans. 🔹 Coinsurance is generally calculated using a drug’s negotiated price before manufacturer rebates. Those rebates can reduce an employer’s net cost without reducing what the patient pays at the pharmacy. --- The number of tiers doesn't say much about what happens to the patient. Deductibles, premiums, employer contributions, out-of-pocket limits, and the medications a patient needs all matter when comparing plans. For employers: How much of reported savings come from a lower drug cost, and how much come from a higher patient contribution? Read the full analysis. 👇🏻 The State of Employer Pharmacy Benefits in 2026: When Plan Savings Come From Higher Patient Costs drugch.nl/3UGskNm

Post attachment
Drug Channels avatar
Drug Channels@DrugChannels·Nov 9

The U.S. doesn’t have one health insurance system. It has a patchwork of public programs and private plans. Plus millions still uninsured. --- According to the U.S. Census Bureau: 🔵 65.7% had private coverage at some point during the year. 🔵 35.8% had public coverage, including Medicare and Medicaid. 🔴 7.9% (26.7 million people) were uninsured for the entire year. (Note: The coverage categories overlap because people can have more than one type of coverage during the year) Employment-based coverage was the largest source of insurance, covering 53.5% of the population. --- Even among people with private insurance, the patient experience can look very different. ↳ Deductibles, copayments, coinsurance, drug coverage, and pharmacy networks vary across plans. So knowing how many people have coverage is just a starting point. The details of that coverage are also important, particularly as coverage has been becoming less rich due to rising costs. More on that in the blog tomorrow 😉 Are you surprised we still had ~27 million people uninsured last year?

Post attachment